Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT

• Status: Completed
• Trial end date: 2013-03-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving more than one chemotherapy drug with radiation therapy may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving intrathecal and systemic combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed central nervous system (CNS) atypical teratoid/rhabdoid tumors.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dana-Farber Cancer Institute
• Collaborator: National Cancer Institute (NCI)
• Treatments: Calcium; Calcium, Dietary; Cisplatin; Cortisol succinate; Cyclophosphamide; Cytarabine; Dactinomycin; Dexrazoxane; Doxorubicin; Etoposide; Hydrocortisone; Hydrocortisone 17-butyrate 21-propionate; Hydrocortisone acetate; Hydrocortisone hemisuccinate; Lenograstim; Leucovorin; Levoleucovorin; Liposomal doxorubicin; Methotrexate; Razoxane; Temozolomide; Vincristine

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed primary intracranial Central Nervous System (CNS) atypical teratoid/rhabdoid tumor OR

• Tumor tissue that possesses the INI-1 gene mutation

• No metastases that disseminate outside the CNS by abdominal and chest computer tomography (CT) scans, kidney imaging, and bone marrow biopsy

• No obstruction of cerebrospinal fluid (CSF) flow by CSF flow study

• Definitive surgical resection of tumor within the past 35 days

PATIENT CHARACTERISTICS:

Age

• 18 and under

Performance status

• Karnofsky 50-100% OR

• Lansky 50-100%

Life expectancy

• Not specified

Hematopoietic

• Hemoglobin > 10 g/dL

• Absolute neutrophil count > 1,000/mm^3

• Platelet count > 100,000/mm^3

Hepatic

• Bilirubin ≤ 1.5 mg/dL

• SGPT < 10 times normal

Renal

• Creatinine ≤ 1.5 times normal

Other

• Willing to have placement of central venous access line

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Not specified

Chemotherapy

• No prior chemotherapy

Endocrine therapy

• Prior steroids allowed

Radiotherapy

• No prior radiotherapy

Surgery

• See Disease Characteristics

Other

• No other prior or concurrent investigational agents

• Concurrent anticonvulsant agents allowed